Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Eligible for screening study DCP 001
NRG GI004 reopened to accrual effective January, 29, 2021.
NCT#02997228Site Delegation of Tasks Log required prior to registration of any patients.